Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Adjuvant radiotherapy increases 5-year disease-free survival by 15.6% in WHO grade 2 atypical meningioma patients after complete resection.

• Why it matters: Atypical meningiomas have a high recurrence risk despite surgery, and the optimal post-surgical treatment to prevent recurrence remains uncertain, impacting patient outcomes.
• What they did: An international phase 3 trial randomized 157 patients to receive either radiotherapy or observation, with a median follow-up of 64 months, assessing disease-free survival and adverse events.
• The result: Radiotherapy significantly improved disease-free survival (hazard ratio 0.51) with manageable serious adverse events, supporting its consideration to reduce tumor recurrence in suitable patients.